HomeCompareANZBY vs ABBV

ANZBY vs ABBV: Dividend Comparison 2026

ANZBY yields 163.14% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANZBY wins by $1.14M in total portfolio value
10 years
ANZBY
ANZBY
● Live price
163.14%
Share price
$16.05
Annual div
$26.18
5Y div CAGR
-15.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.25M
Annual income
$164,385.57
Full ANZBY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ANZBY vs ABBV

📍 ANZBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANZBYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANZBY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANZBY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANZBY
Annual income on $10K today (after 15% tax)
$13,867.25/yr
After 10yr DRIP, annual income (after tax)
$139,727.73/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ANZBY beats the other by $118,671.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANZBY + ABBV for your $10,000?

ANZBY: 50%ABBV: 50%
100% ABBV50/50100% ANZBY
Portfolio after 10yr
$673.7K
Annual income
$94,578.66/yr
Blended yield
14.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ANZBY
Analyst Ratings
2
Hold
1
Sell
Consensus: Hold
Price Target
$24.85
+54.8% upside vs current
Range: $24.85 — $24.85
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANZBY buys
2
ABBV buys
0
PoliticianChamberTickerTypeAmountDate
Greg Gianforte🏢 House$ANZBY▲ Buy$15,001 - $50,0002020-11-13
Greg Gianforte🏢 House$ANZBY▲ Buy$15,001 - $50,0002020-03-18
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANZBYABBV
Forward yield163.14%3.06%
Annual dividend / share$26.18$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-15.6%40.6%
Portfolio after 10y$1.25M$102.3K
Annual income after 10y$164,385.57$24,771.77
Total dividends collected$992.2K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$24.85$256.15

Year-by-year: ANZBY vs ABBV ($10,000, DRIP)

YearANZBY PortfolioANZBY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$24,469$13,769.37$11,550$430.00+$12.9KANZBY
2$52,759$26,576.35$13,472$627.96+$39.3KANZBY
3$101,650$45,198.53$15,906$926.08+$85.7KANZBY
4$177,456$68,690.74$19,071$1,382.55+$158.4KANZBY
5$284,467$94,588.96$23,302$2,095.81+$261.2KANZBY
6$423,982$119,602.36$29,150$3,237.93+$394.8KANZBY
7$594,270$140,609.23$37,536$5,121.41+$556.7KANZBY
8$791,326$155,456.46$50,079$8,338.38+$741.2KANZBY
9$1,010,001$163,282.13$69,753$14,065.80+$940.2KANZBY
10$1,245,086$164,385.57$102,337$24,771.77+$1.14MANZBY

ANZBY vs ABBV: Complete Analysis 2026

ANZBYStock

Australia and New Zealand Banking Group Limited provides various banking and financial products and services in Australia and internationally. Its Australia Retail and Commercial division offers various products and services to consumer customers through the branch network, mortgage specialists, contact centers, self-service channels, and third-party brokers, as well as financial planning services. It also provides asset financing for medium to large commercial customers, agribusiness customers, small business owners, high net worth individuals, and family groups. The company's Institutional division offers documentary trade, supply chain and commodity financing, cash management solutions, deposits, payments, and clearing services; loan syndication, loan structuring and execution, project and export finance, debt structuring and acquisition finance, and corporate advisory services, as well as loan products; and risk management services. It serves governments, and global institutional and corporate customers. The company's New Zealand division provides banking and wealth management services to consumer, and private banking and small business banking customers through its Internet and app-based digital solutions, network of branches, mortgage specialists, relationship managers, and contact centers; and traditional relationship banking and financial solutions for medium to large enterprises, agricultural business segments, and government and government-related entities. Its Pacific division offers retail products, and traditional relationship banking and financial solutions. This division serves retail customers, small to medium-sized enterprises, institutional customers, and governments. Australia and New Zealand Banking Group Limited has a strategic partnership with Cashrewards Limited to launch Cashrewards MaxTM for Australia and New Zealand consumer credit and debit card holders. The company was founded in 1835 and is headquartered in Melbourne, Australia.

Full ANZBY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ANZBY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANZBY vs SCHDANZBY vs JEPIANZBY vs OANZBY vs KOANZBY vs MAINANZBY vs JNJANZBY vs MRKANZBY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.